Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis
Open Access
- 15 November 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 13 (11) , e1002169
Abstract
Stroke is a leading cause of death and disability; worldwide it is estimated that 16.9 million people have a first stroke each year. Lipid-lowering, anticoagulant, and antihypertensive drugs can prevent strokes, but may be underused. We analysed anonymised electronic primary care records from a United Kingdom (UK) primary care database that covers approximately 6% of the UK population. Patients with first-ever stroke/transient ischaemic attack (TIA), ≥18 y, with diagnosis between 1 January 2009 and 31 December 2013, were included. Drugs were considered under-prescribed when lipid-lowering, anticoagulant, or antihypertensive drugs were clinically indicated but were not prescribed prior to the time of stroke or TIA. The proportions of strokes or TIAs with prevention drugs under-prescribed, when clinically indicated, were calculated. In all, 29,043 stroke/TIA patients met the inclusion criteria; 17,680 had ≥1 prevention drug clinically indicated: 16,028 had lipid-lowering drugs indicated, 3,194 anticoagulant drugs, and 7,008 antihypertensive drugs. At least one prevention drug was not prescribed when clinically indicated in 54% (9,579/17,680) of stroke/TIA patients: 49% (7,836/16,028) were not prescribed lipid-lowering drugs, 52% (1,647/3,194) were not prescribed anticoagulant drugs, and 25% (1,740/7,008) were not prescribed antihypertensive drugs. The limitations of our study are that our definition of under-prescribing of drugs for stroke/TIA prevention did not address patients’ adherence to medication or medication targets, such as blood pressure levels. In our study, over half of people eligible for lipid-lowering, anticoagulant, or antihypertensive drugs were not prescribed them prior to first stroke/TIA. We estimate that approximately 12,000 first strokes could potentially be prevented annually in the UK through optimal prescribing of these drugs. Improving prescription of lipid-lowering, anticoagulant, and antihypertensive drugs is important to reduce the incidence and burden of stroke and TIA.Keywords
Funding Information
- National Institute for Health Research School for Primary Care Research (NIHR SPCR)
- National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Health Research and Care for West Midlands (CLAHRC-WM) (None)
This publication has 40 references indexed in Scilit:
- Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional studyBMJ Open, 2013
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative studyBMC Family Practice, 2011
- EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countriesEuropean Journal of Preventive Cardiology, 2010
- Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative studyBMC Family Practice, 2009
- Barriers to adherence to hypertension guidelines among GPs in southern Sweden: A surveyScandinavian Journal of Primary Health Care, 2008
- Hypertension guideline recommendations in general practice: awareness, agreement, adoption, and adherenceBritish Journal of General Practice, 2007
- Hypertension Treatment and Control in Five European Countries, Canada, and the United StatesHypertension, 2004
- Why Don't Physicians Follow Clinical Practice Guidelines?JAMA, 1999
- Stroke Severity in Atrial FibrillationStroke, 1996